On Jul. 20, 2020, Luminex announced the FDA had issued an Emergency Use Authorization for the company’s xMAPﾮ SARS-CoV-2 Multi-Antigen IgG Assay. Clinical laboratories can now use this serology assay to identify the presence of antibodies in people who have been infected with the virus that causes COVID-19.

The test can be run on any of Luminex’s xMAP-based high-throughput, gold-standard multiplex platforms, providing a more comprehensive and reliable assessment of immune response compared to conventional serology testing methods.